Analysts at Raymond James assumed coverage on shares of Nuvectra (NASDAQ:NVTR) in a report released on Monday, The Fly reports. The firm set an “outperform” rating on the stock.

A number of other analysts also recently weighed in on NVTR. Zacks Investment Research downgraded Nuvectra from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. BidaskClub downgraded Nuvectra from a “buy” rating to a “hold” rating in a research report on Saturday, November 10th. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 target price on shares of Nuvectra in a research report on Wednesday, August 8th. Finally, JMP Securities upped their target price on Nuvectra from $18.00 to $23.00 and gave the company a “market outperform” rating in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.50.

NVTR opened at $18.44 on Monday. The firm has a market capitalization of $324.71 million, a P/E ratio of -4.37 and a beta of -0.34. The company has a quick ratio of 7.35, a current ratio of 7.63 and a debt-to-equity ratio of 0.42. Nuvectra has a 1 year low of $7.60 and a 1 year high of $25.17.

Nuvectra (NASDAQ:NVTR) last released its earnings results on Monday, October 29th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.01). The company had revenue of $14.22 million for the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. On average, research analysts expect that Nuvectra will post -3.44 EPS for the current fiscal year.

In other news, President Joseph Paul Hanchin sold 1,600 shares of the company’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $18.18, for a total transaction of $29,088.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of NVTR. First Manhattan Co. acquired a new position in shares of Nuvectra during the 2nd quarter worth $102,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Nuvectra during the 2nd quarter worth $105,000. MetLife Investment Advisors LLC acquired a new position in shares of Nuvectra during the 2nd quarter worth $148,000. GSA Capital Partners LLP acquired a new position in shares of Nuvectra during the 3rd quarter worth $201,000. Finally, Financial Architects Inc raised its holdings in shares of Nuvectra by 300.0% during the 2nd quarter. Financial Architects Inc now owns 10,000 shares of the company’s stock worth $205,000 after buying an additional 7,500 shares in the last quarter. 70.72% of the stock is owned by institutional investors.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.

Featured Article: No Load Funds

The Fly

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.